Weight loss, diabetes drugs propel Eli Lilly to largely bett

Eli Lilly rode soaring demand for diabetes and weight-loss treatments to a better-than-expected finish in 2023, and the drugmaker expects momentum to carry into the new year.

Related Keywords

North Carolina , United States , David Ricks , Eli Lilly , Drug Administration , Wall Street , Indianapolis Based Eli Lilly ,